Zhejiang Cancer Hospital

🇨🇳China

Country: 🇨🇳China

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.zchospital.com

Clinical Trials

Interleukin-11 Can Prevent and Treat of Radioactive Oral Mucitis

Phase 3

Conditions: Nasopharyngeal Carcinoma

Interventions: Drug: Saline
Drug: Recombinant Human Interleukin-11

First Posted Date: 2018-10-25

Last Posted Date: 2020-08-11

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 300

Registration Number: NCT03720340

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

A Prospective Randomized Trial of Capecitabine Treatment in Patients With HNSCC

Phase 2

Conditions: Head and Neck Neoplasms

Interventions: Drug: Capecitabine

First Posted Date: 2018-09-19

Last Posted Date: 2018-09-19

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 180

Registration Number: NCT03678649

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

PET/MR in Locally Advanced Nasopharyngeal Carcinoma

Not Applicable

Recruiting

Conditions: PET/MR
Nasopharyngeal Carcinoma

Interventions: Diagnostic Test: PET/MR

First Posted Date: 2018-09-04

Last Posted Date: 2018-09-04

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 150

Registration Number: NCT03657017

Locations: 🇨🇳
Xiaozhong Chen, Hangzhou, Zhejiang, China

Abraxane Combined With Xeloda as Neo-Adjuvant Chemotherapy in Early Breast Cancer

Not Applicable

Conditions: Breast Cancer

Interventions: Drug: Abraxane
Drug: Xeloda

First Posted Date: 2018-08-27

Last Posted Date: 2018-12-10

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 50

Registration Number: NCT03647514

The Efficacy and Safety of Abraxane Combined With Epirubicin as Neoadjuvant Chemotherapy in Breast Cancer

Not Applicable

Conditions: Breast Cancer

Interventions: Drug: Abraxane
Drug: Epirubicin

First Posted Date: 2018-08-27

Last Posted Date: 2018-12-07

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 50

Registration Number: NCT03647280

Predictor Analysis of Acute Radiation Oral Mucositis in NPC Patients Treated With IMRT/TOMO Combined Chemotherapy

Conditions: Nasopharyngeal Carcinoma

First Posted Date: 2018-08-27

Last Posted Date: 2018-08-27

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 200

Registration Number: NCT03647527

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

Recurrence Score-guiding Chemotherapy in Non-pCR HR Positive HER2 Negative Breast Cancer After Neoadjuvant Therapy

Phase 2

Conditions: Breast Cancer

Interventions: Drug: Capecitabine

First Posted Date: 2018-08-20

Last Posted Date: 2019-09-10

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 80

Registration Number: NCT03638648

Prophylactic Use of PEG-rhG-CSF in Medium-high Risk of FN in Chemotherapy of Breast Cancer

Conditions: Febrile Neutropenia

Interventions: Drug: PEGCSF first level prophylactic use
Drug: PEGCSF second level prophylactic use

First Posted Date: 2018-08-07

Last Posted Date: 2018-12-27

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 2000

Registration Number: NCT03618810

Application of Circulating Tumor DNA Test in the Diagnosis and Treatment of Patients With Advanced Rectal Cancer

Conditions: Rectal Neoplasms
Circulating Tumor DNA
Neoadjuvant Therapy

First Posted Date: 2018-08-03

Last Posted Date: 2019-05-29

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 200

Registration Number: NCT03615170

Locations: 🇨🇳
Zhejiang Cancer Hospital, Hangzhou, Zhejiang, China

TOMO Versus IMRT in Nasopharyngeal Carcinoma Patients

Conditions: Nasopharyngeal Carcinoma

Interventions: Radiation: IMRT
Radiation: TOMO

First Posted Date: 2018-07-17

Last Posted Date: 2018-07-20

Lead Sponsor: Zhejiang Cancer Hospital

Target Recruit Count: 110

Registration Number: NCT03588403

Locations: 🇨🇳
Xiaozhong Chen, Hangzhou, Zhejiang, China

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy